OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
- PMID: 31782764
- DOI: 10.1093/brain/awz366
OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
Erratum in
-
Erratum.Brain. 2020 Mar 1;143(3):e24. doi: 10.1093/brain/awaa007. Brain. 2020. PMID: 32333675 Free PMC article. No abstract available.
Comment in
-
Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine.Brain. 2020 Jan 1;143(1):e6. doi: 10.1093/brain/awz368. Brain. 2020. PMID: 31782777 Free PMC article. No abstract available.
Comment on
-
Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.Brain. 2019 May 1;142(5):1203-1214. doi: 10.1093/brain/awz052. Brain. 2019. PMID: 30982843 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
